Alexandra Blackman, Amy C Rees, Robert R Bowers, Christian M Jones, Silvia G Vaena, Madison A Clark, Shelby Carter, Evan D Villamor, Della Evans, Anthony J Emanuel, George Fullbright, David T Long, Laura Spruill, Martin J Romeo, Kristi L Helke, Joe R Delaney
Genetically engineered mouse models (GEMM) have fundamentally changed how ovarian cancer etiology, early detection, and treatment is understood. However, previous GEMMs of high-grade serous ovarian cancer (HGSOC) have had to utilize genetics rarely or never found in human HGSOC to yield ovarian cancer within the lifespan of a mouse. MYC , an oncogene, is amongst the most amplified genes in HGSOC, but it has not previously been utilized to drive HGSOC GEMMs. We coupled Myc and dominant negative mutant p53-R270H with a fallopian tube epithelium-specific promoter Ovgp1 to generate a new GEMM of HGSOC...
January 29, 2024: bioRxiv